February 26, 2013 at 20:34 PM EST
Zogenix Unlikely to Receive Action Letter for NDA for Zohydro ER by PDUFA Goal Date of March 1, 2013
Zogenix (NASDAQ: ZGNX ), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that Zogenix is unlikely to receive an action letter for its New Drug
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here